Glucagon and insulin have opposite effects on tissue chromium distribution in an obese mouse model
Chang Lin†, Po-Wen Chen‡, Wen-Ying Chen, Chi-Ching Sun, Frank Chiahung Mao*

ABSTRACT
Aims/Introduction: Previous studies have suggested that chromium (Cr) is an essential cofactor for normal carbohydrate metabolism and affects insulin sensitivity, especially in rodent models. Several factors, such as insulin challenge, high carbohydrate intake, and response to stress (e.g., in obesity), alter Cr excretion or distribution. Glucagon is known to regulate carbohydrate metabolism and hyperglucagonemia plays a role in the development of hyperglycemia in diabetic subjects.

Materials and Methods: In the present study we investigated possible modulation of Cr levels by glucagon using an obese mouse model. Mice were kept on a high-fat diet and then used as an obesity model. These obese mice were injected with one dose of glucagon or insulin and Cr levels in their tissues were determined.

Results: In obese mice, glucagon challenge significantly increased Cr levels in bone but decreased them in the fat and liver. In contrast, insulin challenge significantly decreased Cr levels in bone but increased them in the fat, liver, and muscle.

Conclusions: The results show that glucagon and insulin have opposite effects on Cr levels in bone, fat, liver, and muscle. (J Diabetes Invest, doi: 10.1111/jdi.12097, 2013)

KEY WORDS: Chromium, Glucagon, Insulin

INTRODUCTION
Trivalent chromium (Cr) is considered an essential cofactor for normal carbohydrate, lipid, and protein metabolism. For example, previous studies have suggested the importance of Cr as a cofactor for effective insulin responses, and have demonstrated that Cr is transported to tissues to bind chromodulin and form a biologically active compound. Thus, it is important to understand tissue Cr distribution.

Some studies have demonstrated that hyperglucagonemia, or an elevated glucagon-to-insulin ratio, plays an important role in the development of hyperglycemia in diabetic subjects. Treatment to reduce glucagon levels has been shown to reduce blood glucose levels and alleviate symptoms of hyperglycemia, thus confirming the importance of glucagon in diabetes. However, the exact mechanisms of action of glucagon and its possible effects on Cr levels in diabetic or obese subjects remain unclear. Conversely, high carbohydrate intake and some stress factors have been reported to promote Cr excretion in the urine. Therefore, in the present study we evaluated the role of glucagon in modulation of Cr levels in obese mice. Our results should improve the current understanding of the role of glucagon in modulation of Cr levels.

MATERIALS AND METHODS
Cr-containing milk powder
Powder containing 325 p.p.m. trivalent Cr, Cr chloride hexahydrate, lactoferrin, whey protein concentrate, and powdered milk (1:6:200:393) was provided by Maxluck Biotechnology Corporation (Taipei, Taiwan). This milk powder has been examined and shown to be biologically active in a previous study.

Animals, diet, and tissue preparation
Fifty-two male C57BL/6J Narl mice were maintained at a constant temperature of 22 ± 2°C and under a 12-h light–dark cycle, with free access to food and water. Mice were divided into the following four experimental groups on the basis of the type of chow fed: (i) normal chow (5008 Rodent LabDiet; PMI Nutrition International, St Louis, MO, USA); (ii) high-fat chow (high-fat Rodent TestDiet; PMI Nutrition International; 67% of calories provided by fat); (iii) high-fat chow supplemented with placebo milk; and (iv) high-fat chow supplemented with Cr-containing milk (40 μg/kg bodyweight per day). Mice were fed high-fat chow for 4 weeks to obtain a diet-induced obesity model. The obese mice were further divided into two groups: one group was fed placebo milk and the other was fed Cr-containing milk daily by oral gavage for another 4 weeks. Mice were anesthetized and then killed by cervical dislocation,
and bone, epididymal fat, liver, and gastrocnemius muscle were harvested and stored at $-20^\circ$C until analysis. In all animal experiments, the authors adhered to the guidelines for the Care and Use of Laboratory Animals, as recommended by the Taiwanese Government. Note, all animal tests described below were performed at the end of the feeding protocol just before mice were killed.

**Insulin or glucagon challenge**
After 8 weeks, mice were injected with glucagon (200 µg/kg, i.p.; Sigma, St Louis, MO, USA), insulin (2 IU/kg, i.p.; Lilly, Indianapolis, IN, USA), or saline (control group). Blood samples were collected 1 h after injection and blood glucose levels were determined.

**Biochemical analyses**
After 8 weeks feeding, blood samples were collected from overnight-fasted mice. Blood glucose was measured using a glucometer (One Touch II; LifeScan, Milpitas, GA, USA). Serum insulin and glucagon concentrations were measured using commercially available ELISA kits, namely the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem, Chicago, IL, USA) and the Glucagon Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturers’ instructions.

**Cr analysis**
Tissue concentrations of Cr were determined as reported previously. Briefly, tissue samples were digested in 65% nitric acid and heated at 65°C for 1 h. Cr levels were determined using graphite furnace atomic absorption spectrophotometry (Hitachi Z-2000 series polarized Zeeman atomic absorption spectrophotometer; Hitachi Co. Ltd, Tokyo, Japan).

**Glucose tolerance test**
Mice were subjected to a glucose tolerance test as described previously. Briefly, mice were fasted overnight and then injected with glucose (0.5 g/kg, i.p.). Blood samples were collected from the tail vein at 0, 30, 90 and 180 min after injection, and blood glucose concentrations determined by the glucose oxidase reaction.

**Statistical analysis**
Data are expressed as mean ± SD. The significance of differences was evaluated using Student’s $t$-test in Microsoft EXCEL (Microsoft, Richmond, WA, USA). $P < 0.05$ was considered significant.

**RESULTS**

**Effects of a high-fat diet on Cr distribution in mice**
As indicated in Figure 1a, all mice became obese after feeding of the high-fat chow, and the blood glucose levels in these obese mice tended to be slightly higher than those in mice fed normal chow (Figure 1b). In addition, Cr levels in the blood of obese mice were significantly higher than those in mice fed normal chow (Table 1). In contrast, Cr levels in the bone, fat, liver, and muscle of obese mice were significantly lower than those in mice fed normal chow (Table 1). These findings confirm that a high-fat diet has a negative effect on Cr accumulation in selected tissues.

**Effects of glucagon or insulin on blood glucose, serum glucagon, and insulin in obese mice**
In obese mice, 4 weeks of placebo or chromium supplementation had a negligible effect on blood glucose levels (Table 2). One hour after bolus injection of glucagon, blood glucose levels...
glucagon or insulin (supplemented with chromium-containing or placebo milk for an additional 4 weeks. These mice were then injected intraperitoneally with saline, glucagon or insulin (n = 7 in each group) and blood glucose levels were determined 1 h later.

Table 2 | Blood glucose levels after saline, glucagon or insulin challenge in obese mice supplemented with placebo or chromium-containing milk

| Blood glucose (mg/dL) | Placebo | Chromium |
|---------------------|---------|----------|
| Baseline            | 104.7 ± 14.4 | 100.1 ± 5.1 |
| 1 h                 | 1060 ± 12.4  | 1057 ± 9.4  |

Data are the mean ± SD. *P < 0.05 compared with baseline. Mice were fed high-fat chow for 4 weeks and then fed with the same diets supplemented with chromium-containing or placebo milk for an additional 4 weeks. These mice were then injected intraperitoneally with saline, glucagon or insulin (n = 7 in each group) and blood glucose levels were determined 1 h later.

Effects of glucagon or insulin on Cr distribution in obese mice

To investigate the role of glucagon in modulation of tissue Cr levels in obese mice, the effects of glucagon challenge on tissue Cr distribution were analyzed. For comparison, one experimental group was challenged with insulin. As shown in Figure 2, glucagon challenge significantly increased Cr levels in bone, but decreased Cr levels in fat and liver. In contrast, insulin challenge significantly decreased Cr levels in bone, but increased them in fat, liver, and muscle. These findings show that glucagon and insulin have opposite effects on Cr levels in these selected tissues. Similar results have been found using other obese (B6.V-Lepr<sup>ob</sup>/J) and diabetic (BKS.Cg-Lepr<sup>ob</sup>/Lepr<sup>ob</sup>) mouse models (C-C Sun, unpubl. obs., 2006).

The above data demonstrate that glucagon has opposite effects on Cr accumulation to insulin. Previously, we showed that Cr supplementation effectively increased Cr levels in serum, muscle, and fat<sup>10</sup>. Then, we were interested to investigate whether dietary Cr supplementation was capable of reversing tissue Cr levels in obese animals. In preliminary studies, the change in tissue chromium was most obvious in the 1 h after glucagon and insulin challenge. Moreover, tissue chromium levels were evaluated in obese mice 4 h after challenge with saline, glucagon, and insulin. Chromium supplementation significantly increased chromium levels in fat 4 h after saline, glucagon, and insulin challenge (data not shown). Thus, we investigated chromium tissue levels 1 h after glucagon and insulin challenge. The Cr supplementation protocol used in the present study has been reported previously to effectively increase Cr levels in serum, muscle, and fat<sup>10</sup>. In saline-challenged mice, chromium

Table 3 | Serum levels of glucagon and insulin after saline, glucagon or insulin challenge in obese mice supplemented with placebo or chromium-containing milk

| Glucagon (pg/mL) | Placebo | Chromium |
|------------------|---------|----------|
| Baseline         | 1943 ± 58.8 | 1384 ± 35.5 |
| 1 h              | 3338 ± 26.3  | 195.5 ± 49.2  |

Data are the mean ± SD. *P < 0.05 compared with saline challenge. Mice were fed high-fat chow for 4 weeks and then fed with the same diets supplemented with chromium-containing or placebo milk for an additional 4 weeks. These mice were then injected intraperitoneally with saline, glucagon or insulin (n = 7 in each group) and serum levels of glucagon and insulin were determined 1 h later.

Figure 2 | Glucagon and insulin have opposite effects on tissue chromium (Cr) distribution in obese mice. Mice were fed high-fat chow for 8 weeks and then injected intraperitoneally with saline (control; n = 7), glucagon (n = 7), or insulin (n = 7). Tissues samples were harvested and Cr levels measured 1 h after injection. Values are the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the saline control.
supplementation significantly increased Cr levels in fat, liver, and muscle compared with the placebo group (Table 4). As indicated in Table 4, Cr levels in fat and liver of glucagon-challenged mice increased significantly after administration of additional dietary Cr. Moreover, Cr levels in insulin-challenged mice increased with the administration of Cr supplements. Relative variations in Cr levels in the tissues listed in Table 4 were also calculated; Cr levels in a given tissue from the control group (supplemented with placebo milk and challenged with either glucagon or insulin) were subtracted from Cr levels in the same tissue from Cr-supplemented groups (challenged with glucagon or insulin), and the result was divided by Cr levels in the same tissue from the control group. Administration of a Cr supplement to glucagon-challenged mice increased Cr levels in fat, liver, and muscle by >30%, and slightly increased Cr levels in fat, liver, and muscle by 20–30% in insulin-challenged mice.

**DISCUSSION**

The results of the present study show that a high-fat diet has a negative effect on Cr accumulation in tissues. In a recent report, Cr was shown to be a non-essential trace element in terms of body composition, glucose metabolism, and insulin sensitivity in a rodent model. The authors also concluded that previously reported results of Cr supplementation should be treated as pharmacological effects. However, it is believed that Cr should be considered a cofactor, especially in individuals with certain disorders. In support of this, Cr has been shown to activate glucose transporter four trafficking and enhance insulin-stimulated glucose transport in 3T3-L1 adipocytes. Moreover, in our rodent models, Cr supplementation has attenuated hepatic damage in a rat model of chronic cholestasis and has helped attenuate high-fat diet-induced non-alcoholic fatty liver disease in KK/HJ mice. Furthermore, Cr supplementation enhances insulin signaling in skeletal muscle in an obese KK/HJ diabetic mouse model. Collectively, the data suggest that a high-fat diet could contribute to the detrimental effects caused by changes in Cr accumulation within insulin-sensitive tissues. Of note, the present study has demonstrated that mice fed a high-fat diet have decreased Cr levels in bone compared with normal healthy mice. The role of Cr in bone is unclear and needs to be investigated further. In the present study, plasma insulin levels in mice fed the normal diet and high-fat diet were 420 ± 153 and 303 ± 43 pg/mL, respectively. Insulin measurements revealed that feeding of the high-fat diet did not cause hyperinsulinemia. The homeostatic Cr levels in tissues were produced by the interplay between the high-fat diet and insulin, and favored the former. After injection of a bolus of insulin, plasma insulin levels increased to 3875 ± 45 pg/mL. We believe that these high insulin levels override the effects of the high-fat diet on chromium mobilization and reversed tissue Cr levels in obese animals.

Our results demonstrate that glucagon and insulin challenge have opposite effects on tissue Cr distribution in obese mice. It has been shown that physiological insulin indirectly promotes Cr mobilization to insulin-sensitive tissues, possibly in association with the effect of insulin on glucose transport. In agreement with these findings, the present study shows that insulin injection promotes Cr accumulation in fat, liver, and muscle. Intriguingly, glucagon is a counterregulatory hormone to insulin, and the present study provides interesting data on modulation of Cr levels by glucagon and insulin. As mentioned above, chromium uptake is glucose dependent in insulin-sensitive tissues. Therefore, the effects of both insulin and glucagon on tissue Cr distribution may all be secondary to the effects of these hormones on glucose uptake in liver, muscle, and fat.

Previous studies have reported that hyperglucagonemia, or an elevated glucagon-to-insulin ratio, plays an important role in the development of hyperglycemia in diabetes. Hyperglucagonemia destabilizes normal blood glucose control mostly because of glucagon-mediated increases in blood glucose levels. In the present study, we have shown that the effect of glucagon on Cr levels in tissues may also contribute, in part,

**Table 4 | Tissue chromium levels after saline, glucagon or insulin challenge in obese mice supplemented with placebo or chromium-containing milk**

| Chromium (p.p.b.) | Placebo challenge | Glucagon challenge | Insulin challenge |
|------------------|-------------------|--------------------|------------------|
|                  | Blood             | Bone               | Fat              | Liver             | Muscle             | Blood             | Bone               | Fat              | Liver             | Muscle             | Blood             | Bone               | Fat              | Liver             | Muscle             |
| Placebo challenge | 243 ± 60          | 94 ± 32            | 27 ± 4           | 30 ± 4           | 28 ± 6           | 257 ± 67          | 469 ± 110         | 20 ± 2           | 20 ± 3           | 27 ± 7           | 216 ± 24          | 65 ± 9             | 68 ± 7             | 77 ± 30           | 40 ± 11           |
| Chromium         | 256 ± 58          | 245 ± 144*         | 34 ± 10          | 44 ± 12*         | 38 ± 9           | 267 ± 53          | 306 ± 98*         | 28 ± 4***        | 26 ± 6*          | 36 ± 10†         | 234 ± 19†         | 56 ± 12            | 91 ± 31†           | 96 ± 34†          | 42 ± 11           |

Data are the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 compared with placebo; †P < 0.1 compared with placebo. Mice were fed high-fat chow for 4 weeks and then fed with the same diets supplemented with chromium-containing or placebo milk for an additional 4 weeks. These mice were then injected intraperitoneally with saline, glucagon or insulin (n = 7 in each group) and tissue chromium levels were determined 1 h later.
to impairment of blood glucose control in terms of Cr modulation by glucagon.

We also examined and confirmed the role of glucagon in tissue Cr distribution in other obese and diabetic animal models (data not shown), and found that glucagon challenge significantly decreased Cr levels in epididymal fat, liver, and muscle, and increased Cr levels in bone. Using three types of animal models, our studies clearly demonstrate that glucagon challenge has a negative effect on Cr accumulation in insulin-sensitive tissues.

In conclusion, the present study demonstrates that both a high-fat diet and glucagon challenge can decrease Cr levels in tissues. Of note, as discussed above, the role of glucagon in tissue Cr distribution may be secondary to the effects of the hormone on glucose uptake in tissues. However, our findings support the assumption that the detrimental effects of a high fat intake and hyperglucagonemia in diabetics could be associated with changes in tissue Cr levels. Further studies are needed to elucidate the mechanisms involved.

ACKNOWLEDGEMENTS

This work was supported, in part, by the National Science Council (grants NSC100-2320-B-562-001 and NSC 100-2313-B-562-001), grants from St. Mary’s Medicine, Nursing and Management College (SMC100-I-14 and SMC 102-I-04), and the Ministry of Education (Taiwan) under the Aim for the Top University (ATU) plan. None of the authors has any conflict of interest to declare.

REFERENCES

1. Pechova A, Pavlata L. Chromium as an essential nutrient: a review. Vet Med 2007; 52: 1–18.
2. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004; 27: 2741–2751.
3. Vincent JB. The biochemistry of chromium. J Nutr 2000; 130: 715–718.
4. Muller WA, Faloona GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283: 109–115.
5. Reaven GM, Chen YD, Golay A, et al. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 106–110.
6. Johnson DG, Goebel CJ, Hruby VJ, et al. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 1982; 215: 1115–1116.
7. Qureshi SA, Rios CM, Xie D, et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 2004; 53: 3267–3273.
8. Anderson RA. Chromium as an essential nutrient for humans. Regul Toxicol Pharmacol 1997; 26(Suppl): S35–S41.
9. Morris BW, Griffiths H, Kemp GJ. Effect of glucose loading on concentrations of chromium in plasma and urine of healthy adults. Clin Chem 1988; 34: 1114–1116.
10. Chen WY, Chen CJ, Liu CH, et al. Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HJ diabetic mice. Diabetes Obes Metab 2009; 11: 293–303.
11. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res 1990; 31: 859–869.
12. Polotsky VY, Li J, Punjabi NM, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 2003; 552: 253–264.
13. Di Bona KR, Love S, Rhodes NR, et al. Chromium is not an essential trace element for mammals: effects of a “low-chromium” diet. J Biol Inorg Chem 2011; 16: 381–390.
14. Chen G, Liu P, Pattar GR, et al. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 2006; 20: 857–870.
15. Chen WY, Chen CJ, Liao JW, et al. Chromium attenuates hepatic damage in a rat model of chronic cholestasis. Life Sci 2009; 84: 606–614.
16. Chen WY, Chen CJ, Liu CH, et al. Chromium attenuates high-fat diet-induced nonalcoholic fatty liver disease in KK/HJ mice. Biochem Biophys Res Commun 2010; 397: 459–464.
17. Borguet F, Comelis R, Lameire N. Speciation of chromium in plasma and liver tissue of endstage renal failure patients on continuous ambulatory peritoneal dialysis. Biol Trace Elem Res 1990; 26–27: 449–460.
18. Clodfelder BJ, Emamaullee J, Hepburn DD, et al. The trail of chromium(III) in vivo from the blood to the urine: the roles of transferrin and chromodulin. J Biol Inorg Chem 2001; 6: 608–617.
19. Clodfelder BJ, Vincent JB. The time-dependent transport of chromium in adult rats from the bloodstream to the urine. J Biol Inorg Chem 2005; 10: 383–393.
20. Sun Y, Ramirez J, Woski SA, et al. The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LWMCr) and the transfer of chromium from transferrin and chromium picolinate to LMWCr. J Biol Inorg Chem 2000; 5: 129–136.